TPX2, a critical target of KRAS, has been reported to be involved in the development of pancreatic ductal adenocarcinoma (PDAC) through the regulation of hypoxia-mediated HIF-1 [27]. Here, TPX2 is linked to pancreatic ductal adenocarcinoma.